[HTML][HTML] NODDI in clinical research

K Kamiya, M Hori, S Aoki - Journal of neuroscience methods, 2020 - Elsevier
Diffusion MRI (dMRI) has proven to be a useful imaging approach for both clinical diagnosis
and research investigating the microstructures of nervous tissues, and it has helped us to …

[HTML][HTML] Systematic review: quantitative susceptibility mapping (QSM) of brain iron profile in neurodegenerative diseases

P Ravanfar, SM Loi, WT Syeda… - Frontiers in …, 2021 - frontiersin.org
Iron has been increasingly implicated in the pathology of neurodegenerative diseases. In
the past decade, development of the new magnetic resonance imaging technique …

CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease

A Southon, K Szostak, KM Acevedo… - British journal of …, 2020 - Wiley Online Library
Background and Purpose Diacetyl‐bis (4‐methyl‐3‐thiosemicarbazonato) copperII (CuII
(atsm)) ameliorates neurodegeneration and delays disease progression in mouse models of …

MRI biomarkers for memory-related impairment in amyotrophic lateral sclerosis: a systematic review

S Ghaderi, F Fatehi, S Kalra… - … Lateral Sclerosis and …, 2023 - Taylor & Francis
Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder associated
with cognitive and behavioral impairments and motor symptoms. Magnetic resonance …

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS

NA Goyal, JD Berry, A Windebank, NP Staff… - Muscle & …, 2020 - Wiley Online Library
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder with
complex biology and significant clinical heterogeneity. Many preclinical and early phase …

[HTML][HTML] Tracking a fast-moving disease: longitudinal markers, monitoring, and clinical trial endpoints in ALS

RH Chipika, E Finegan, S Li Hi Shing… - Frontiers in …, 2019 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes
with different progression rates, varying degree of extra-motor involvement and divergent …

Connectome‐based propagation model in amyotrophic lateral sclerosis

JM Meier, HK van Der Burgh, AD Nitert… - Annals of …, 2020 - Wiley Online Library
Objective Clinical trials in amyotrophic lateral sclerosis (ALS) continue to rely on survival or
functional scales as endpoints, despite the emergence of quantitative biomarkers …

Focus on the heterogeneity of amyotrophic lateral sclerosis

C Bendotti, V Bonetto, E Pupillo… - … Lateral Sclerosis and …, 2020 - Taylor & Francis
The clinical manifestations of amyotrophic lateral sclerosis (ALS) are variable in terms of age
at disease onset, site of onset, progression of symptoms, motor neuron involvement, and the …

Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behçet's syndrome

A Bettiol, M Becatti, E Silvestri… - Clinical & …, 2021 - academic.oup.com
Behçet's syndrome (BS) is a systemic vasculitis with several clinical manifestations.
Neutrophil hyperactivation mediates vascular BS pathogenesis, via both a massive reactive …

[HTML][HTML] Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics

C Schuster, O Hardiman, P Bede - BMC neurology, 2017 - Springer
Background Amyotrophic lateral sclerosis (ALS) a highly heterogeneous neurodegenerative
condition. Accurate diagnostic, monitoring and prognostic biomarkers are urgently needed …